Why the study?
Severely elevated LDL-C in HoFH starts in utero and accelerates atherosclerosis, creating an unmet need for aggressive LDLR-independent lipid-lowering therapies in pediatric patients.
Does intravenous evinacumab reduce LDL-C in pediatric patients with homozygous familial hypercholesterolemia inadequately controlled on optimized lipid-lowering therapy?
Does intravenous evinacumab reduce LDL-C in pediatric patients with homozygous familial hypercholesterolemia inadequately controlled on optimized lipid-lowering therapy?
Evinacumab safely and effectively reduces LDL-C by nearly half in pediatric patients aged 5 to 11 years with homozygous familial hypercholesterolemia who are inadequately controlled on optimized lipid-lowering therapy.
Answers are grounded in this paper and cite their sources.
May support LDL-C lowering with evinacumab in young HoFH patients; leaves open need for randomized outcome trials.
BACKGROUND: Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder characterized by severely elevated low-density lipoprotein cholesterol (LDL-C) levels due to profoundly defective LDL receptor (LDLR) function. Given that severely elevated LDL-C starts in utero, atherosclerosis often presents during childhood or adolescence, creating a largely unmet need for aggressive LDLR-independent lipid-lowering therapies in young patients with HoFH. Here we present the first evaluation of the efficacy and safety of evinacumab, a novel LDLR-independent lipid-lowering therapy, in pediatric patients with HoFH from parts A and B of a 3-part study. METHODS: The phase 3, part B, open-label study treated 14 patients 5 to 11 years of age with genetically proven HoFH (true homozygotes and compound heterozygotes) with LDL-C >130 mg/dL, despite optimized lipid-lowering therapy (including LDLR-independent apheresis and lomitapide), with intravenous evinacumab 15 mg/kg every 4 weeks. RESULTS: Evinacumab treatment rapidly and durably (through week 24) decreased LDL-C with profound reduction in the first week, with a mean (SE) LDL-C reduction of -48.3% (10.4%) from baseline to week 24. ApoB (mean [SE], -41.3% [9.0%]), non-high-density lipoprotein cholesterol (-48.9% [9.8%]), and total cholesterol (-49.1% [8.1%]) were similarly decreased. Treatment-emergent adverse events were reported in 10 (71.4%) patients; however, only 2 (14.3%) reported events that were considered to be treatment-related (nausea and abdominal pain). One serious treatment-emergent adverse event of tonsillitis occurred (n=1), but this was not considered treatment-related. CONCLUSIONS: Evinacumab constitutes a new treatment for pediatric patients with HoFH and inadequately controlled LDL-C despite optimized lipid-lowering therapy, lowering LDL-C levels by nearly half in these extremely high-risk and difficult-to-treat individuals. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04233918.
No takes yet. Share an insight, caveat, or question.
Wiegman et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: